Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 1.37
GNOM's Cash to Debt is ranked lower than
99.99% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GNOM: 1.37 )
Ranked among companies with meaningful Cash to Debt only.
GNOM' s Cash to Debt Range Over the Past 10 Years
Min: 0.34  Med: 2.47 Max: 5.3
Current: 1.37
0.34
5.3
Interest Coverage -25.40
GNOM's Interest Coverage is ranked lower than
99.99% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNOM: -25.40 )
Ranked among companies with meaningful Interest Coverage only.
GNOM' s Interest Coverage Range Over the Past 10 Years
Min: -25  Med: -16.90 Max: -10
Current: -25.4
-25
-10
F-Score: 3
M-Score: -1.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -358.20
GNOM's Operating margin (%) is ranked lower than
99.99% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. GNOM: -358.20 )
Ranked among companies with meaningful Operating margin (%) only.
GNOM' s Operating margin (%) Range Over the Past 10 Years
Min: -5390.9  Med: -507.50 Max: -358.2
Current: -358.2
-5390.9
-358.2
Net-margin (%) -374.00
GNOM's Net-margin (%) is ranked lower than
99.99% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. GNOM: -374.00 )
Ranked among companies with meaningful Net-margin (%) only.
GNOM' s Net-margin (%) Range Over the Past 10 Years
Min: -5770.3  Med: -614.40 Max: -374
Current: -374
-5770.3
-374
ROE (%) -87.60
GNOM's ROE (%) is ranked lower than
99.99% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. GNOM: -87.60 )
Ranked among companies with meaningful ROE (%) only.
GNOM' s ROE (%) Range Over the Past 10 Years
Min: -87.6  Med: -82.95 Max: -78.3
Current: -87.6
-87.6
-78.3
ROA (%) -55.60
GNOM's ROA (%) is ranked lower than
99.99% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. GNOM: -55.60 )
Ranked among companies with meaningful ROA (%) only.
GNOM' s ROA (%) Range Over the Past 10 Years
Min: -118.7  Med: -55.90 Max: -55.6
Current: -55.6
-118.7
-55.6
ROC (Joel Greenblatt) (%) -278.00
GNOM's ROC (Joel Greenblatt) (%) is ranked lower than
99.99% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. GNOM: -278.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNOM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -348  Med: -266.80 Max: -197.2
Current: -278
-348
-197.2
» GNOM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNOM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
GNOM's P/B is ranked lower than
99.99% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. GNOM: 2.20 )
Ranked among companies with meaningful P/B only.
GNOM' s P/B Range Over the Past 10 Years
Min: 0.85  Med: 1.94 Max: 6.81
Current: 2.2
0.85
6.81
P/S 4.75
GNOM's P/S is ranked lower than
99.99% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. GNOM: 4.75 )
Ranked among companies with meaningful P/S only.
GNOM' s P/S Range Over the Past 10 Years
Min: 1.48  Med: 4.49 Max: 9.89
Current: 4.75
1.48
9.89
Current Ratio 1.06
GNOM's Current Ratio is ranked lower than
99.99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GNOM: 1.06 )
Ranked among companies with meaningful Current Ratio only.
GNOM' s Current Ratio Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 1.06
Quick Ratio 3.27
GNOM's Quick Ratio is ranked lower than
99.99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GNOM: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
GNOM' s Quick Ratio Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 3.27

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.80
GNOM's Price/Net Current Asset Value is ranked lower than
99.99% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. GNOM: 10.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNOM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 6.9  Med: 14.40 Max: 41.3
Current: 10.8
6.9
41.3
Price/Tangible Book 2.30
GNOM's Price/Tangible Book is ranked lower than
99.99% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GNOM: 2.30 )
Ranked among companies with meaningful Price/Tangible Book only.
GNOM' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.2  Med: 1.70 Max: 3.7
Current: 2.3
1.2
3.7
Price/Median PS Value 0.70
GNOM's Price/Median PS Value is ranked lower than
99.99% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. GNOM: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
GNOM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.4  Med: 0.85 Max: 1.5
Current: 0.7
0.4
1.5

More Statistics

Revenue(Mil) $22
EPS $ -2.34
Short Percentage of Float0.00%
52-Week Range $1.57 - 4.25
Shares Outstanding(Mil)34.49

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Complete Genomics Inc was incorporated in Delaware in June 2005 and began operations in March 2006. The Company is a life sciences company that has developed and commercialized an innovative DNA sequencing platform that it believes will become the preferred solution for complete human genome sequencing and analysis. Complete Genomics Analysis Platform, or CGA Platform, combines its proprietary human genome sequencing technology with its advanced informatics and data management software and its innovative, end-to-end, outsourced service model to provide its customers with data that is immediately ready to be used for genome-based research. The Company's solution will provide academic and biopharmaceutical researchers with complete human genomic data and analysis at an unprecedented quality, cost and scale without requiring them to invest in in-house sequencing instruments, high-performance computing resources and specialized personnel. The Company has targeted its complete human genome sequencing service at academic, governmental and other research institutions, as well as pharmaceutical and other life science companies. It performs its sequencing service at its Mountain View, California headquarters facility, which began commercial operation in May 2010. In the near term, it expects to make significant expenditures related to the expansion of its Mountain View sequencing facility and its research and development initiatives, as well as to increase its sales and marketing and general and administrative expenses to support its commercial operations and anticipated growth. In future years, The Company plans to construct additional genome centers in the United States and in other strategic markets to accommodate an expected growing global demand for high-quality, low-cost complete human genome sequencing on a large scale. The Company competes with Illumina, Inc., Life Technologies Corporation and Roche Diagnostics Corporation.
» More Articles for GNOM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK